Skip to content

The Actual News

Stay informed without the news wearing you out.

Experimental drug shows promise against deadly pancreatic cancer

Experimental drug shows promise against deadly pancreatic cancer

Summary

A new pill called daraxonrasib helped people with advanced pancreatic cancer live almost twice as long compared to standard chemotherapy. The drug targets a common mutation in the cancer and showed fewer severe side effects, offering hope for better treatment.

Key Facts

  • Daraxonrasib blocks a mutated protein linked to over 90% of pancreatic cancers.
  • In a study with 500 patients, those taking the drug lived 13.2 months on average versus 6.7 months with chemotherapy.
  • The drug caused fewer serious side effects, mainly skin rash and mouth sores.
  • Patients stayed on daraxonrasib longer and reported less pain and better quality of life.
  • The study results were published in the New England Journal of Medicine and announced at a major cancer meeting.
  • The FDA plans to speed up the review of daraxonrasib and is allowing expanded access for some patients.
  • Pancreatic cancer is very deadly, with about 67,000 new U.S. cases and 52,000 deaths expected this year.
  • Researchers hope the drug could be useful earlier in treatment and might help more patients become eligible for surgery.
Read the Full Article

This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.

The week's biggest stories, one calm email every Monday.